AstraZeneca’s Soriot Outlines Epanova Approach, Reviews Tough First Year As CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca’s two-pronged approach to get its experimental fish oil-based heart drug Epanova approved by U.S. regulators is on track according to CEO Pascal Soriot. But an FDA Advisory Committee’s negative recommendation for Amarin’s similar drug, Vascepa, likely means the second step, seeking a label expansion for Epanova in a broader, less seriously ill population, will have to await full outcomes data.
You may also be interested in...
AstraZeneca’s Epanova: Third In Omega-3 Market, Potentially First With Larger Population Claim
Fish oil treatment is the first to offer a dosing regimen of as few as two capsules, once a day, with our without food, AstraZeneca said.
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.